Coloma Jason V sold $174K of MAZE (indirect holdings)
Coloma Jason V (Chief Executive Officer) sold 6,643 indirectly-held shares of Maze Therapeutics, Inc. (MAZE) at an average of $26.20 ($26.20–$26.24, $0.17M total) across 2 trades on 2026-06-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
A modest insider sell may cause short‑term price dip but is unlikely to affect long‑term outlook.
Market read
Provides fresh, primary‑source data on insider activity for traders monitoring MAZE.
What to watch
Potential upcoming clinical data releases that may offset any short‑term pressure.
Background
Form 4 filing discloses insider transactions required by the SEC.
Ticker impact
CEO Jason V. Coloma sold 6,643 shares for $174K via a 10b5‑1 plan, reducing his stake to 27,970 shares.
likely slight downward pressure as the market prices the insider sell.
Small transaction size relative to market cap, but insider sales are watched by traders.
Market effects
Minimal impact on the biotech sector; insider sales are routine.
No significant regional effect.
Limited to investors tracking MAZE.
Counterpoint
The sale could be a routine liquidity move and not indicative of negative fundamentals.
Key entities
- CompanyMaze Therapeutics, Inc.
Biotech firm listed on NASDAQ under ticker MAZE.
- PersonJason V. Coloma
Chief Executive Officer of Maze Therapeutics.
